Condition: Diabetes · Diabetes Melletus, Type 1 · Diabetes Mellitus, Type 2 · Sponsor: Senseonics, Inc.
The purpose of this clinical investigation is to demonstrate that the proposed physical changes to the ROME GS Sensor do not have any adverse impact on safety and performance when compared to the Eversense 365 Sensor.
This description comes directly from the study's public registry record.
Maggie Lewis · 667-218-3309 · maggie.lewis@senseonics.com
Susan Huynh · 301-407-2923 · susan.huynh@senseonics.com
Always discuss trial participation with your own doctor first.
| Headlands Research - AMCR Institute | Escondido, California, United States | Recruiting |
| Flourish Research - Diablo Clinical Research | Walnut Creek, California, United States | Not Yet Recruiting |
| Flourish Research - San Antonio | San Antonio, Texas, United States | Recruiting |
| Rainier Clinical Research Center | Renton, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07518004